Author: Han, Lu ; Liu, Xue ; Yuan, Long ; Wang, Yao ; Zhang, Kuang ; Li, Tiepeng ; Li, Linlin ; Gao, Quanli ; Qin, Peng ; Guo, Jindong ; Zhang, Yong ; Xu, Benling ; Chen, Guangyu ; Zhang, Mengyu ; Yuan, Peng ; You, Hongqin

Adoptive cell therapy (ACT) has revolutionized the treatment of patients with cancer. The success of ACT depends largely on transferred T cell status, particularly their less-differentiated state with stem cell-like properties, which enhances ACT effectiveness. Stem cell-like memory T (T_SCM) cells exhibit continuous self-renewal and multilineage differentiation similar to pluripotent stem cells. T_SCM cells are promising candidates for cancer immunotherapies, whereas maintenance of a more stem-cell-like state before transfer is challenging. Here, we established a highly efficient protocol for generating CD8⁺ T_SCM cells from peripheral blood mononuclear cells (PBMCs). The process involved activating PBMCs using anti-CD3 monoclonal antibody and RetroNectin, followed by a transient-resting culture period (24 h) and subsequent long-term expansion in vitro with interlukien-2. We report that this transient-resting culture after activation preserves CD8⁺ T cells in a stem memory phenotype (CD95⁺ CD45RA⁺ CCR7⁺) compared to the conventional culture method. Further, this approach reduces the expression of T cell immunoglobulin mucin-3, an exhaustion marker, and increases the expression of T cell factor-1, a master regulator of stemness even after long-term culture compared to the conventional culture method. In conclusion, our study presents a simplified and cost-effective method for generating and expanding CD8⁺ T_SCM cells ex vivo. This approach streamlines the optimization of cancer immunotherapy using ACT.

01 Jan 2024·Methods in Molecular Biology

Expansion and Retroviral Transduction of Primary Murine T Cells for CAR T-Cell Therapy

Article

Author: Short, Lauralie ; Evgin, Laura ; Savage, Gillian ; Loos, Pauline

The development of chimeric antigen receptor (CAR) T cells has been a revolutionary technology for the treatment of relapsed and refractory leukemias and lymphomas. The synthetic CAR molecule redirects T cell function toward tumor surface-expressed antigens through a single-chain variable fragment (scFv) fused to CD3z and intracellular costimulatory domains. Here, we describe a protocol for the generation of CAR T cells using primary mouse T cells and a gammaretroviral vector encoding a CAR transgene. This protocol outlines several transduction and expansion methods based on the use of two transduction enhancers, RetroNectin^® and Vectofusin^®-1, and cell culture systems such as conventional plates or G-Rex^® devices.

01 Jan 2022·BIO-PROTOCOL

High-Efficiency Retroviral Transduction for Type 1 Regulatory T Cell Differentiation

Article

Author: August, Avery ; McGee, Michael C ; Huang, Weishan

Type 1 regulatory T (Tr1) cells are an immunoregulatory CD4 ⁺ Foxp3- IL-10 ^high T cell subset with therapeutic potential for various inflammatory diseases. Retroviral (RV) transduction has been a valuable tool in defining the signaling pathways and transcription factors that regulate Tr1 differentiation and suppressive function. This protocol describes a method for RV transduction of naïve CD4 ⁺ T cells differentiating under Tr1 conditions, without the use of reagents such as polybrene or RetroNectin. A major advantage of this protocol over others is that it allows for the role of genes of interest on both differentiation and function of Tr1 cells to be interrogated. This is due to the high efficiency of RV transduction combined with the use of an IL10 ^GFP /Foxp3 ^RFP dual reporter mouse model, which enables successfully transduced Tr1 cells to be identified and sorted for functional assays. In addition, this protocol may be utilized for dual/multiple transduction approaches and transduction of other lymphocyte populations, such as CD8 ⁺ T cells.

100 Deals associated with Retronectin-induced T cell therapy (Takara Bio)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cancer	Phase 2	JP	Takara Bio, Inc.	-
Liver Cancer	Phase 2	JP	Kyoto Prefectural University of Medicine	-
Lung Cancer	Phase 2	JP	Kyoto Prefectural University of Medicine	-
Neoplasms	Phase 2	CN	Tianjin Cancer Institute	-
Neoplasms	Phase 2	CN	Takara Bio, Inc.	-
Pancreatic Carcinoma	Phase 2	JP	Kyoto Prefectural University of Medicine	-
Pancreatic Carcinoma	Phase 2	JP	Takara Bio, Inc.	-
Gastrointestinal Neoplasms	Phase 1	JP	Takara Bio, Inc.	-
Gastrointestinal Neoplasms	Phase 1	JP	Kyoto Prefectural University of Medicine	-
Lung Cancer	Phase 1	JP	Takara Bio, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Retronectin-induced T cell therapy (Takara Bio)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation